* Genelabs Technologies Inc., of Redwood City, Calif.,said the first phase of financing for its joint venture withthe Taiwan government, called Genelabs BiotechnologyLtd., has been completed, in the amount of $14.6 million.The new company, which will focus on late-stagedevelopment and commercialization of new andformulated products in Asia, is 40 percent owned byGenelabs, 35 percent by the Taiwan government and 25percent by private investors. (See BioWorld Today, July18, 1995, p. 1.)
* Guilford Pharmaceuticals Inc., of Baltimore, licensedrights to a biodegradable polymer from Yissum ResearchDevelopment Corp. of the Hebrew University ofJerusalem, which it intends to develop for the delivery ofdrugs for cancer.
* Ribi ImmunoChem Research Inc., of Hamilton, Mont.,said preclinical data on its MPL-C immunomodulatorshowed it reduced cardiac infarct size apparently byacting through a cellular electrophysiologic systembelieved to be important in cardioprotection againstischemia and reperfusion injury.
* Transcell Technologies Inc., a Princeton, N.J., majority-held subsidiary of Interneuron Pharma-ceuticals Inc.,received a $100,000 Phase I small business innovationresearch grant to evaluate its drug transport technology indelivering antisense compounds.
(c) 1997 American Health Consultants. All rights reserved.